Tamarind trypsin inhibitor in chitosan–Whey protein nanoparticles reduces fasting blood glucose levels without compromising Insulinemia: a preclinical study

In vivo studies show the benefits of the trypsin inhibitor isolated from tamarind (Tamarindusindica L.) (TTI) seeds in satiety and obesity. In the present study, TTI nanoencapsulation (ECW) was performed to potentialize the effect of TTI and allow a controlled release in the stomach. The impact on g...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Principais autores: Morais, Ana Heloneida de Araújo, Matias, Lidia Leonize Rodrigues, Costa, Rafael Oliveira de Araújo, Passos, Thais Souza, Queiroz, Jaluza Luana Cravalho de, Serquiz, Alexandre Coelho, Maciel, Bruna Leal Lima, Santos, Pedro Paulo de Andrade, Camillo, Cristina da Silva, Gonçalves, Catarina, Amado, Izabel Rodriguez, Pastrana, Lorenzo
Outros Autores: https://orcid.org/0000-0002-6460-911X
Formato: article
Idioma:English
Publicado em: Nutrients
Assuntos:
Tamarindusindica L.
encapsulation
overfeeding
digestion
fasting glucose
insulin
Endereço do item:https://repositorio.ufrn.br/handle/123456789/54725
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
id ri-123456789-54725
record_format dspace
spelling ri-123456789-547252023-09-06T19:57:20Z Tamarind trypsin inhibitor in chitosan–Whey protein nanoparticles reduces fasting blood glucose levels without compromising Insulinemia: a preclinical study Morais, Ana Heloneida de Araújo Matias, Lidia Leonize Rodrigues Costa, Rafael Oliveira de Araújo Passos, Thais Souza Queiroz, Jaluza Luana Cravalho de Serquiz, Alexandre Coelho Maciel, Bruna Leal Lima Santos, Pedro Paulo de Andrade Camillo, Cristina da Silva Gonçalves, Catarina Amado, Izabel Rodriguez Pastrana, Lorenzo https://orcid.org/0000-0002-6460-911X Tamarindusindica L. encapsulation overfeeding digestion fasting glucose insulin In vivo studies show the benefits of the trypsin inhibitor isolated from tamarind (Tamarindusindica L.) (TTI) seeds in satiety and obesity. In the present study, TTI nanoencapsulation (ECW) was performed to potentialize the effect of TTI and allow a controlled release in the stomach. The impact on glycemia, insulin, and lipid profile was evaluated in Wistar rats overfed with a high glycemic index diet (HGLI). Characterization of the nanoparticles and in vitro stability in simulated gastrointestinal conditions, monitored by antitrypsin activity and HPLC, was performed. ECW and empty nanoparticles (CW) were administered by gavage, using 12.5 and 10.0 mg/kg, respectively. Both nanoformulations presented a spherical shape and smooth surface, with an average diameter of 117.4 nm (24.1) for ECW and 123.9 nm (11.3) for CW. ECW maintained the antitrypsin activity (95.5%) in the gastric phase, while TTI was completely hydrolyzed. In Wistar rats, the nanoformulations significantly reduced glycemia and HOMA IR, and ECW increased HDL-c compared to CW (p < 0.05).Pancreas histopathology of animals treated with ECW suggested an onset of tissue repair. Thenanoencapsulation provided TTI protection, gradual release in the desired condition, and improvement of biochemical parameters related to carbohydrate metabolism disorders,without compromising insulinemia 2023-09-06T19:57:20Z 2023-09-06T19:57:20Z 2019 article MATIAS, Lídia L. R. et al. Tamarind trypsin inhibitor in chitosan–whey protein nanoparticles reduces fasting blood glucose levels without compromising insulinemia: a preclinical study. Nutrients, v. 11, n. 11, p. 2770, 2019.Disponível em: https://www.mdpi.com/2072-6643/11/11/2770. Acesso em: 7 jul. 2023. https://repositorio.ufrn.br/handle/123456789/54725 10.3390/nu11112770 en application/pdf Nutrients
institution Repositório Institucional
collection RI - UFRN
language English
topic Tamarindusindica L.
encapsulation
overfeeding
digestion
fasting glucose
insulin
spellingShingle Tamarindusindica L.
encapsulation
overfeeding
digestion
fasting glucose
insulin
Morais, Ana Heloneida de Araújo
Matias, Lidia Leonize Rodrigues
Costa, Rafael Oliveira de Araújo
Passos, Thais Souza
Queiroz, Jaluza Luana Cravalho de
Serquiz, Alexandre Coelho
Maciel, Bruna Leal Lima
Santos, Pedro Paulo de Andrade
Camillo, Cristina da Silva
Gonçalves, Catarina
Amado, Izabel Rodriguez
Pastrana, Lorenzo
Tamarind trypsin inhibitor in chitosan–Whey protein nanoparticles reduces fasting blood glucose levels without compromising Insulinemia: a preclinical study
description In vivo studies show the benefits of the trypsin inhibitor isolated from tamarind (Tamarindusindica L.) (TTI) seeds in satiety and obesity. In the present study, TTI nanoencapsulation (ECW) was performed to potentialize the effect of TTI and allow a controlled release in the stomach. The impact on glycemia, insulin, and lipid profile was evaluated in Wistar rats overfed with a high glycemic index diet (HGLI). Characterization of the nanoparticles and in vitro stability in simulated gastrointestinal conditions, monitored by antitrypsin activity and HPLC, was performed. ECW and empty nanoparticles (CW) were administered by gavage, using 12.5 and 10.0 mg/kg, respectively. Both nanoformulations presented a spherical shape and smooth surface, with an average diameter of 117.4 nm (24.1) for ECW and 123.9 nm (11.3) for CW. ECW maintained the antitrypsin activity (95.5%) in the gastric phase, while TTI was completely hydrolyzed. In Wistar rats, the nanoformulations significantly reduced glycemia and HOMA IR, and ECW increased HDL-c compared to CW (p < 0.05).Pancreas histopathology of animals treated with ECW suggested an onset of tissue repair. Thenanoencapsulation provided TTI protection, gradual release in the desired condition, and improvement of biochemical parameters related to carbohydrate metabolism disorders,without compromising insulinemia
author2 https://orcid.org/0000-0002-6460-911X
author_facet https://orcid.org/0000-0002-6460-911X
Morais, Ana Heloneida de Araújo
Matias, Lidia Leonize Rodrigues
Costa, Rafael Oliveira de Araújo
Passos, Thais Souza
Queiroz, Jaluza Luana Cravalho de
Serquiz, Alexandre Coelho
Maciel, Bruna Leal Lima
Santos, Pedro Paulo de Andrade
Camillo, Cristina da Silva
Gonçalves, Catarina
Amado, Izabel Rodriguez
Pastrana, Lorenzo
format article
author Morais, Ana Heloneida de Araújo
Matias, Lidia Leonize Rodrigues
Costa, Rafael Oliveira de Araújo
Passos, Thais Souza
Queiroz, Jaluza Luana Cravalho de
Serquiz, Alexandre Coelho
Maciel, Bruna Leal Lima
Santos, Pedro Paulo de Andrade
Camillo, Cristina da Silva
Gonçalves, Catarina
Amado, Izabel Rodriguez
Pastrana, Lorenzo
author_sort Morais, Ana Heloneida de Araújo
title Tamarind trypsin inhibitor in chitosan–Whey protein nanoparticles reduces fasting blood glucose levels without compromising Insulinemia: a preclinical study
title_short Tamarind trypsin inhibitor in chitosan–Whey protein nanoparticles reduces fasting blood glucose levels without compromising Insulinemia: a preclinical study
title_full Tamarind trypsin inhibitor in chitosan–Whey protein nanoparticles reduces fasting blood glucose levels without compromising Insulinemia: a preclinical study
title_fullStr Tamarind trypsin inhibitor in chitosan–Whey protein nanoparticles reduces fasting blood glucose levels without compromising Insulinemia: a preclinical study
title_full_unstemmed Tamarind trypsin inhibitor in chitosan–Whey protein nanoparticles reduces fasting blood glucose levels without compromising Insulinemia: a preclinical study
title_sort tamarind trypsin inhibitor in chitosan–whey protein nanoparticles reduces fasting blood glucose levels without compromising insulinemia: a preclinical study
publisher Nutrients
publishDate 2023
url https://repositorio.ufrn.br/handle/123456789/54725
work_keys_str_mv AT moraisanaheloneidadearaujo tamarindtrypsininhibitorinchitosanwheyproteinnanoparticlesreducesfastingbloodglucoselevelswithoutcompromisinginsulinemiaapreclinicalstudy
AT matiaslidialeonizerodrigues tamarindtrypsininhibitorinchitosanwheyproteinnanoparticlesreducesfastingbloodglucoselevelswithoutcompromisinginsulinemiaapreclinicalstudy
AT costarafaeloliveiradearaujo tamarindtrypsininhibitorinchitosanwheyproteinnanoparticlesreducesfastingbloodglucoselevelswithoutcompromisinginsulinemiaapreclinicalstudy
AT passosthaissouza tamarindtrypsininhibitorinchitosanwheyproteinnanoparticlesreducesfastingbloodglucoselevelswithoutcompromisinginsulinemiaapreclinicalstudy
AT queirozjaluzaluanacravalhode tamarindtrypsininhibitorinchitosanwheyproteinnanoparticlesreducesfastingbloodglucoselevelswithoutcompromisinginsulinemiaapreclinicalstudy
AT serquizalexandrecoelho tamarindtrypsininhibitorinchitosanwheyproteinnanoparticlesreducesfastingbloodglucoselevelswithoutcompromisinginsulinemiaapreclinicalstudy
AT macielbrunaleallima tamarindtrypsininhibitorinchitosanwheyproteinnanoparticlesreducesfastingbloodglucoselevelswithoutcompromisinginsulinemiaapreclinicalstudy
AT santospedropaulodeandrade tamarindtrypsininhibitorinchitosanwheyproteinnanoparticlesreducesfastingbloodglucoselevelswithoutcompromisinginsulinemiaapreclinicalstudy
AT camillocristinadasilva tamarindtrypsininhibitorinchitosanwheyproteinnanoparticlesreducesfastingbloodglucoselevelswithoutcompromisinginsulinemiaapreclinicalstudy
AT goncalvescatarina tamarindtrypsininhibitorinchitosanwheyproteinnanoparticlesreducesfastingbloodglucoselevelswithoutcompromisinginsulinemiaapreclinicalstudy
AT amadoizabelrodriguez tamarindtrypsininhibitorinchitosanwheyproteinnanoparticlesreducesfastingbloodglucoselevelswithoutcompromisinginsulinemiaapreclinicalstudy
AT pastranalorenzo tamarindtrypsininhibitorinchitosanwheyproteinnanoparticlesreducesfastingbloodglucoselevelswithoutcompromisinginsulinemiaapreclinicalstudy
_version_ 1777022468243849216

Registros relacionados